This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nathan's Most Recent Article

A Buysider's Preview of Biotech's Biggest Conference

01/02/13 - 07:00 AM EST

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

read more >

Other Articles by Nathan

Free Reports

Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up

08/06/12 - 07:00 AM EDT

The two Hep C drugs are similar enough chemically to warrant caution.

read more >
Gilead Sciences Firing On All Cylinders Gilead Sciences Firing On All Cylinders

07/30/12 - 07:00 AM EDT

Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.

read more >
The Health Care Short Sales That Never Fit The Health Care Short Sales That Never Fit

07/23/12 - 07:00 AM EDT

Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.

read more >
Eli Lilly, Verastem and the Defenders of Shareholder Value Eli Lilly, Verastem and the Defenders of Shareholder Value

07/16/12 - 07:07 AM EDT

TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.

read more >
Onyx Pharma Must Start Delivering Profits Onyx Pharma Must Start Delivering Profits

07/10/12 - 08:10 AM EDT

With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.

read more >
ObamaCare Upheld: Health Care Stock Winners and Losers ObamaCare Upheld: Health Care Stock Winners and Losers

06/28/12 - 11:38 AM EDT

TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.

read more >
Arena Pharma And The Fat Lady's Song Arena Pharma And The Fat Lady's Song

06/25/12 - 11:13 AM EDT

Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.

read more >
Alkermes Needs to Build on Drug Delivery Success Alkermes Needs to Build on Drug Delivery Success

06/18/12 - 07:00 AM EDT

An undervalued stock could move higher if Alkermes continues to grow through acquisitions.

read more >
A Reckoning Approaches: Supreme Court and Obama's Healthcare Reform Law A Reckoning Approaches: Supreme Court and Obama's Healthcare Reform Law

06/11/12 - 07:09 AM EDT

Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.

read more >
Bad Romance: Glaxo's Brutal Courtship of Human Genome Sciences Bad Romance: Glaxo's Brutal Courtship of Human Genome Sciences

06/04/12 - 07:45 AM EDT

Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.

read more >
Page 3 of 5
Top Rated Stocks Top Rated Funds Top Rated ETFs